

# **Dewmar International BMC, Inc.**

TIN No. 26-4465583  
State of Incorporation Nevada

**Financial Disclosure Statement for the following reporting periods:**

**3<sup>rd</sup> QTR ended September 30, 2018**

# General Disclosure Information

## 1) Name of issuer

Dewmar International BMC, Inc.

## 2) Address of Issuer's principal executive office

### Company Headquarters

132 E. Northside Drive, Suite C

Clinton, MS 39056

Phone: (601) 488-4360

EMAIL:

info@dewmarinternational.com

Website:

www.DewmarInternational.com

### IR Contact

132 E. Northside Drive, Suite C

Clinton, MS 39056

Phone: (877) 747-5326

EMAIL:

info@dewmarinternational.com

Website:

www.DewmarInternational.com

## 3) Security Information

Trading Symbol: DEWM

### Common Stock

CUSIP: 25211R102

Par or Stated Value: \$ 0 .0001

Total shares authorized: 4,450,000,000 as of: 9/30/18

Total shares outstanding: 2,933,552,401 as of: 9/30/18

Total shares authorized: 4,450,000,000 as of: 12/31/17

Total shares outstanding: 2,933,552,401 as of: 12/31/17

Total shares authorized: 4,450,000,000 as of: 12/31/16

Total shares outstanding: 2,814,542,401 as of: 12/31/16

### Preferred Stock

Par or Stated Value: \$0.001

Total Shares Authorized: 50,000,000 as of: 9/30/18

Total shares outstanding: 50,000,000 as of: 9/30/18

Total Shares Authorized: 50,000,000 as of: 12/31/17

Total shares outstanding: 50,000,000 as of: 12/31/17

Total Shares Authorized: 50,000,000 as of: 12/31/16

Total shares outstanding: 50,000,000 as of: 12/31/16

## Transfer Agent

Empire Stock Transfer  
1859 Whitney Mesa Drive  
Henderson, W 89014  
Phone: 702-818-5898

Empire Stock Transfer is registered under the  
Exchange Act? Yes: ✓

List any restrictions on the transfer of security: **NONE**

List any trading suspension orders issued by the SEC in the past 12 months: **NONE**

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months: **NONE**

## **4) Issuance History**

List below any events, in chronological order, that resulted in changes in total shares outstanding by the issuer in the past two fiscal years and any interim period. The list shall include all offerings of equity securities, including debt convertible into equity securities, whether private or public, and all shares or any other securities or options to acquire such securities issued for services, describing (1) the securities, (2) the persons or entities to whom such securities were issued and (3) the services provided by such persons or entities. The list shall indicate:

On June 21, 2017 a certificate for 15,500,000 unrestricted shares of common stock were issued to a Consultant as a result of the completion of a consulting services settlement agreement dated July 19, 2017 as it relates to a past existing consulting agreement dated October 15, 2013. These shares were deposited into an account in the summer of 2017.

On July 21, 2017 a certificate for 145,000,000 unrestricted shares of common stock were issued to a Consultant in accordance to a consulting agreement dated January 14, 2013. As of this date, these shares are currently still in Certificate Form and have not yet been placed on deposit therefore is not part of the current float.

On July 21, 2017 a certificate for 96,888,888 unrestricted shares of common stock were issued to an investor for payment of a Convertible Promissory Note dated December 23, 2013. These shares have been deposited into an account.

On August 3, 2017 a certificate for 250,000,000 unrestricted shares of common stock were issued to a Consultant in accordance to a consulting agreement dated October 27, 2012. All of these shares have either been transferred to other entities, utilized as collateral on licensing/business deals in the states of Louisiana and Arkansas or negotiated as settlement of other outstanding consulting debts. As of this date, these shares are still in certificate form and have not yet been placed on deposit and therefore are not part of the current float. Dewmar was successful in negotiating terms to have this Consultant forfeit the remaining number of shares that will prevent the issuance of hundreds of millions of additional shares.

On October 10, 2018 the Company entered into a Securities Purchase Agreement with a Canadian company whereas the company purchased Sixty Million (60,000,000) shares of Restricted Common Stock at the price of \$0.0005 per share for total investment of Thirty-Thousand Dollars (\$30,000 USD). As of today's date, these Restricted shares have yet to be issued; they become eligible for deposit in October 2019.

A. The nature of each offering (e.g., Securities Act Rule 504, intrastate, etc.);

All 506(b)

B. Any jurisdictions where the offering was registered or qualified;

N/A

C. The number of shares offered;

567,388,888

D. The number of shares sold;

567,388,888

E. The price at which the shares were offered, and the amount actually paid to the issuer;

See Above.

F. The trading status of the shares; and

See above.

G. Whether the certificates or other documents that evidence the shares contain a legend (1) stating that the shares have not been registered under the Securities Act and (2) setting forth or referring to the restrictions on transferability and sale of the shares under the Securities Act.

Only the 60,000,000 are restricted. They are in book form now but will have the legend if issued in physical certificate.

## **5) Financial Statements**

Following this section on General Disclosure Information are the Balance Sheet, Statement of Operations and Statement of Cash Flows for the full year period of 2017 ended on December 31.

## **6) Describe the Issuer's Business, Products and Services**

### **Business Operations:**

Dewmar International BMC, Inc. is a diversified operating company headquartered in Clinton, Mississippi with additional office locations in New Orleans, Louisiana and Houston, Texas. The Company conducts business across a variegated set of categories and sectors including consumer goods, wholesale trade and brand management services. The company and its subsidiaries develops, markets and distributes functional foods, manufactured goods and a host of professional services across national and international markets through licensing agreements, distribution contracts, fee-for-service arrangements and e-commerce platforms.

### **Brand Management Company (BMC)**

The Brand Management Company division, which is the BMC portion of Dewmar International BMC, Inc., is a leading provider of consumer brands to global markets. The Company's primary business strategy has been the creation, manufacturing, marketing and distribution of its select portfolio of innovative consumer products through established distribution channels inclusive of national and international retailers. BMC's primary source of revenue is through the wholesale of its branded products.

Dewmar's portfolio of consumer brands includes Company-owned and trademarked brands as well as those brands obtained through license and distribution agreements with partner brand owners.

- A. Date and State of Incorporation:** August 15, 2003 in Nevada
- B. The issuer's primary and secondary SIC Codes:**  
Primary: 8741  
Secondary: 5149, 7999, 5812
- C. The issuer's fiscal year end date:** December 31
- D. Principal products or services, and their markets:**  
Beverages, Consumer Goods and Brand Management and Cannabis/Hemp Entertainment.

## **7) Describe the Issuer's Operations and Facilities**

- A.** Manufacturer, wholesaler and marketer of edible relaxation products

Dewmar International established business relationships with a number of contract manufacturers who are contractually obligated to manufacture and produce the Company's two main products, Kush Cakes and Lean Slow Motion Potion. Kush Cakes is a premium relaxation chocolate brownie that is manufactured at a Department of Health certified commercial bakery in Arizona. Lean Slow Motion Potion is a premium relaxation beverage that is manufactured at an Indiana Department of Health certified beverage bottling facility.

Kush Cakes was formulated by the Company's CEO and has been sold at several retailers throughout the United States since 2011. Lean Slow Motion Potion was also formulated by the Company's CEO and has been sold throughout the U.S. market and abroad since 2009. This beverage has been produced in 3 flavors and holds the record for the longest selling relaxation beverage in the history of Walmart.

- B.** Brand manager of owned and licensed Consumer Goods sold at big box retailers

Dewmar International has contracted with a number of consumer goods brands since 2013. The goal of being a brand manager was to prepare small companies, primarily Veteran and minority-owned businesses, for major presentations with buyers from big box retailers. Over the past 5 years Dewmar has introduced over 11 different companies with a multitude of product lines to a host of Walmart buyers in Bentonville, Arkansas. Additionally, the Company has assisted Women-owned businesses and other minority-based companies with free consulting services to help them position themselves for purchase orders and service contracts with big box retailers across the country.

- C.** Restaurant owner of fast casual dining concept in West Monroe, Louisiana

Dewmar International signed a licensing agreement with KW Brands, LLC in June 2017 in order to be the owner of Willie's Duck Diner, LLC a celebrity-based Louisiana Cajun cuisine traditional restaurant. KW Brands is owned by celebrities Kory and Willie Robertson, co-stars of the world renown reality television show Duck Dynasty. Dewmar has the rights to utilize the Willie's Duck Diner brand in order to sale food and merchandise affiliated with the Willie Robertson and other members of the Duck Dynasty family.

- D.** Executive Producer of Cannabis and Hemp Media

Dewmar International's subsidiary, United States Hemp Corporation, has invested in two cannabis media programs which are Weed for Warriors and The Collective. Weed for Warriors is an educational documentary that videos the journey of several disabled veterans traveling from San Francisco, CA to Washington, D.C. on the eve of Veterans Day to promote their primary mission of trying to convince United States government

officials of how medical marijuana can provide beneficial relief for veterans suffering from service related disabilities. The Collective is a business reality television show where cannabis industry entrepreneurs make a presentation to up to 5 panelists. The typical makeup of a panel will be two hedge fund managers or accredited investors, at least two cannabis industry experts and possibly one celebrity guest. Dr. Marco Moran is a rare panelist who plays a dual role as both an investor and healthcare industry expert, has an executive producer role.

Issuers executive offices are located at:

132 E. Northside Drive, Suite C  
Clinton, MS 39056

## 8) Officers, Directors, and Control Persons

### A. Names of Officers, Directors, and Control Persons

Name	Position with the Company	Term of Office
Dr. Marco Moran	Director, CEO, Treas, CFO	September 2009 to Present
J.D. Houston	Director, President & COO	May 1, 2014 to Present
Derrick Brooks	Director	March 19, 2012 to Present

### B. Legal/Disciplinary History

- A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses): Yes.
- The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities: NONE
- A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated: NONE
- The entry of an order by a self-regulatory organization that permanently or temporarily barred suspended or otherwise limited such person's involvement in any type of business or securities activities: NONE

### C. Beneficial Shareholders

Dr. Marco Moran 100% of Series A Preferred Stock -thus having voting control over the corporation.

## 9) Third Party Providers

Please provide the name, address, telephone number, and email address of each of the following outside providers that advise your company on matters relating to operations, business development and disclosure:

### Legal Counsel

Baker Donelson Bearman Caldwell & Berkowitz  
211 Commerce Street  
Suite 800  
Nashville, TN 37201

Waller Lansden Dortch & Davis, LLP  
511 Union Street, Suite 2700  
Nashville, TN 37219

EAD Law Group, LLC  
8275 S. Eastern Suite 200  
Law Vegas, NV 89123

Accountant or Auditor  
B F Borgers CPA PC  
5400 West Cedar Avenue  
Lakewood, CO 80226

Natan & Associates, LLC  
6720 NW 74<sup>th</sup> Court  
Parkland, FL 33067

**10) Issuer Certification**

I, Dr. Marco Moran certify that:

1. I have reviewed this Disclosure Statement Report of Dewmar International BMC, Inc.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

The issuer has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Dewmar International BMC, INC.

---

(Issuer)

November 24, 2018

**By: /s/ Marco Moran (Marco Moran),  
CEO & CFO**

**DEWMAR INTERNATIONAL BMC, INC.**

**UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE  
MONTHS END SEPTEMBER 30, 2018 AND SEPTEMBER 30, 2017**

<b>DEWMAR INTERNATIONAL BMC, INC.</b>			
<b>UNAUDITED CONSOLIDATED BALANCE SHEETS</b>			
		<b>September 30,</b>	<b>December 31,</b>
		<b>2018</b>	<b>2017</b>
<b>ASSETS</b>			
Current assets:			
Cash and cash equivalents		\$ 9,454	\$ 223,551
Accounts receivable		99,704	142,320
Notes receivable		1,150,411	3,316,354
Inventory		50,449	223,684
Prepaid expenses and other current assets		46,000	60,728
Total current assets		<u>1,356,018</u>	<u>3,966,637</u>
Property and equipment, net		300,309	297,244
Other assets		316,410	474,229
Total assets		<u>\$ 1,972,737</u>	<u>\$ 4,738,111</u>
<b>LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)</b>			
Current liabilities:			
Accounts payable and accrued expenses		\$ 1,332,308	\$ 1,052,046
Accrued interest		12,940	16,053
Accrued interest, related party		-	252
Notes payable		1,316,973	1,442,749
Notes payable, related party		410,000	540,000
Convertible notes		154,320	154,320
Derivative liability		281,706	281,706
Total current liabilities		<u>3,508,247</u>	<u>3,487,126</u>
Total liabilities		<u>\$ 3,508,247</u>	<u>\$ 3,487,126</u>
<b>STOCKHOLDERS EQUITY (DEFICIT)</b>			
Preferred Stock; \$0.001 par value 50,000,000 shares authorized; 50,000,000 shares issued and outstanding, respectively		50,000	50,000
Common stock; \$0.001 par value; 4,450,000,000 shares authorized; 2,814,542,401 and 2,814,542,401 shares issued and outstanding		2,814,546	2,814,546
Additional paid in capital		4,419,763	4,419,763
Accumulated deficit		(8,819,820)	(6,033,324)
Total Stockholders' Equity		<u>(1,535,511)</u>	<u>1,250,985</u>
Total Liabilities and Stockholders' Equity		<u>\$ 1,972,736</u>	<u>\$ 4,738,111</u>

**DEWMAR INTERNATIONAL BMC, INC.**

**UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS**

	<b>For the Three Months Ended September 30, 2018</b>	<b>For the Three Months Ended September 30, 2017</b>	<b>For the Nine Months Ended September 30, 2018</b>	<b>For the Nine Months Ended September 30, 2017</b>
Product revenue, net	\$ 50,355	\$ 183,580	\$ 334,058	\$ 615,700
Restaurant revenues	159,861	128,619	562,437	128,619
Commission revenue, net	-	10,009	-	48,538
Total revenue	210,216	322,208	896,495	792,857
Cost of goods sold	78,070	174,744	367,628	346,892
Gross margin	132,146	147,464	528,867	445,965
Operating expenses:			-	
Occupancy and related expenses	75,950	11,985	179,779	36,882
Bad debt expense	2,342,908	-	2,342,908	-
General and administrative expenses	254,276	276,645	515,163	671,890
Contract labor	22,500	130,853	277,514	157,353
Total operating expenses	2,695,634	419,483	3,315,363	866,125
Income(loss) from operations	(2,563,488)	(272,019)	(2,786,496)	(420,160)
Other income (expenses):			-	
Other income (expenses)	-	-	-	-
Total other income and expense	-	-	-	-
Income(loss) from operations	(2,563,488)	(272,019)	(2,786,496)	(420,160)
Provision for income taxes	-	-	-	-
Net income (loss)	\$ (2,563,488)	\$ (272,019)	\$ (2,786,496)	\$ (420,160)
Net income loss per fully diluted share	\$ (0.00)	\$ (0.00)	\$ (0.00)	\$ (0.00)
Weighted-average number of common shares outstanding:				
Basic and diluted	2,814,542,401	2,814,542,401	2,814,542,401	2,814,542,401

<b>DEWMAR INTERNATIONAL BMC, INC.</b>						
<b>UNAUDITED CONSOLIDATED STATEMENT OF CASH FLOWS</b>						
					<b>For the Nine Months Ended September 30, 2018</b>	<b>For the Nine Months Ended September 30, 2017</b>
Cash flows from operating activities:						
Net income (loss)					\$ (2,786,496)	\$ (420,160)
Adjustments to reconcile net loss to cash used in operating activities:						
Depreciation expense						5,663
Changes in operating assets and liabilities:						
Accounts receivable					42,616	(57,383)
Inventory					173,235	(46,611)
Notes receivable					2,165,943	29,789
Prepays					14,728	(4,000)
Other assets					157,819	(31,461)
Accounts payable and accrued expenses					276,897	63,318
Net cash provided by (used in) operating activities					44,744	(460,845)
Cash flows from investing activities:						
Acquisition of capital assets					(3,064)	-
Net cash provided by (used in) financing activities					(3,064)	-
Cash flows from financing activities:						
Repayment of notes payable and notes payable related parties					(255,777)	
Proceeds from the issuance notes payable -related parties						354,129
Net cash provided by (used in) financing activities					(255,777)	354,129
Net increase (decrease) in cash and cash equivalents					(214,097)	(106,716)
Cash and cash equivalents at beginning of period					223,551	180,704
Cash and cash equivalents at end of period					\$ 9,454	\$ 73,988
Supplemental disclosure of cash flow information:						
Cash paid for interest					-	-
Cash paid for income taxes					-	-

# NOTES TO THE FINANCIAL STATEMENTS

## NOTE 1: ORGANIZATION AND MANAGEMENT'S PLANS

With the expanded placement of our branded products in Walmart, we continue to see growth in our traditional business lines of brand management and consumer goods. Simultaneously, we are diversifying into new markets and business opportunities that show high growth potential and leverage our expertise in pharmaceuticals, healthcare and product development. A key initiative is in the cannabis market, which is growing rapidly due to legalization and adoption of products for medicinal, nutraceutical and recreational use.

- We are expanding on the initial success of *Kush Cakes*, with key lessons learned on hemp-infusion techniques and shelf-life stabilization.
- We formed U.S. Hemp Corporation to develop consumer products for food, beverage, nutraceutical and medicinal applications, and establish partnerships and brand alliances to promote our products and the industry in general.
- In addition to product marketing, we provide an array of hemp industry services —under *The Hemp Incubator* trademark—to foster overall market growth, as well as promote our brands. Our services include:
  - Go-to-market consulting and research
  - Brand management
  - Product development and food science testing
  - Third-party manufacturing relationships
  - Warehousing and order fulfillment
- We have also diversified our hemp/cannabis business model that includes a number of other activities to communicate and promote the benefits of the plant without touching the plant or any components of THC.
  - We formed a Historically Black Colleges & Universities (HBCU) program for Hemp and Medicinal Cannabis Research. which shall provide a self-directed on-line learning curriculum, including expert lectures on the legal, agricultural, social and business aspects of the hemp/cannabis industry.
  - We are executive producers of a documentary film, called “Weed for Warriors.”
  - We are executive producers of a business television reality show called “The Collective”

## NOTE 2: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

### Basis of Presentation and Principles of Consolidation

The consolidated financial statements and accompanying notes are prepared in accordance with accounting principles generally accepted in the United States of America. The consolidated financial statements include the accounts of the Company Dewmar, and HWRC. All material intercompany accounts and transactions have been eliminated. Certain amounts in prior periods have been reclassified to conform to current period presentation.

### Cash and Cash Equivalents

Cash and cash equivalents consist primarily of cash on deposit and money market accounts, which are readily convertible into cash and purchased with original maturities of three months or less. These investments are carried at cost, which approximates fair value.

### Investments

Investments in associated companies or ventures are initially recognized at cost less any provision for impairment. The Company assesses investments for impairment whenever events or changes in circumstances indicate that the carrying value of an investment may not be recoverable. If any such indication of impairment exists, the Company makes an estimate of the recoverable amount. If the recoverable amount of the cash-generating unit is less than the value of the investment, the investment is considered to be impaired and is adjusted to its recoverable amount. An impairment loss is recognized immediately in the profit and loss account.

### Cost of Goods Sold

The Company's cost of goods sold includes all costs of beverage production, which primarily consist of raw materials such as concentrate, sugar, aluminum cans, trays, shrink wrap, can ends, labels and packaging materials. Additionally, costs incurred for shipping, handling and warehousing charges are included in cost of goods sold. The Company does not bill customers for cost of shipping unless the Company incurs additional charges such as refusing initial shipment or not being able to receive shipment at their prescheduled time with the freight company.

### Share-Based Compensation

The Company recognizes all share-based payments to employees, including grants of Company stock options to Company employees, as well as other equity-based compensation arrangements, in the financial statements based on the grant date fair value of the awards. Compensation expense is generally recognized over the vesting period. During the years ended December 31, 2014 and 2013, the Company issued no stock options to employees.

### Concentration of Risks

The Company's operations and future business model are dependent in a large part on the Company's ability to execute its business model. The Company's inability to meet its sales objectives may have a material adverse effect on the Company's financial condition.

### Revenue Recognition Policy

The Company recognizes revenue from two primary sources, sales of product and commissions from HWRC. The Company recognizes revenue when a 3rd party confirms receipt of any inbound prescriptions from any registered practitioner that has been referred by HWRC and said prescription has been adjudicated and approved by a third party payer to yield a profit. HWRC is allowed to access this secure, password protected portal for prescription verification and for verification of the total adjudication reimbursement amount and cost of the medication. HWRC receives 50% of the gross profit of all adjudicated prescriptions with the exception of government funded third party plans. Revenue is recognized upon confirmation from the third party of the amount of commission and when cash is received.

The Company recognizes product revenue when the product is received by and title passes to the customer. The Company's standard terms are 'FOB' destination. If a customer receives any product that they consider damaged or unacceptable, the customer must document any such damages or reasons for it not to be accepted on the original invoice upon delivery and then inform the Company within 72 hours of receipt of the product. The Company does not accept returns of product for reasons other than damage.

We record estimates for reductions to revenue for customer programs and incentives, including price discounts, volume-based incentives, and promotions and advertising allowances. Products are sold with extended payment terms not to exceed 120 days. Revenue is shown net of sales allowances on the accompanying statements of operations.

### **NOTE 3: Leadership**

The following paragraphs set forth brief biographical information for company leadership:

#### **Marco Moran, CEO, Secretary, CFO, Treasurer, Director, Chief Accounting Officer**

As Chief Executive Officer Marco Moran has overall responsibility for the Company's performance, developing its strategic plan to advance its mission and to manage shareholders' value through profitable revenue growth.

As a licensed Doctor of Pharmacy and graduate degree in Pharmaceutical Sciences, Dr. Moran has direct oversight of all the company's research and development, quality control and product innovation activity.

Dr. Moran served at the U.S. Naval Hospital in Camp Lejeune, North Carolina as a Medical Service Corp Officer and Pharmacist.

Dr. Moran began his public service career as the Director of Pharmacy and Regulatory Affairs for INO Therapeutics,

Inc. in Port Allen, Louisiana. He has been the pharmacist of record for leading medical providers such as the Mississippi Baptist Health System, River Region Medical Center, Accredo Health, and several retail pharmacy chains. During his time with River Region Medical Center, Dr. Moran managed Six Sigma project teams to assist administration in meeting quality control standards.

In 2008, Dr. Moran launched Unique Beverage Group, LLC, where he developed, and marketed his first mix of branded, functional beverages. Dr. Moran single-handedly introduced relaxation beverages to major beer distributors in the deep Southern United States. The success of these initial products and the relationships formed during this period eventually lead to the development of Lean Slow Motion Potion and the creation of Dewmar International BMC.

*Education:*

Dr. Moran completed his pre-pharmacy studies at Southern University and Louisiana State University in Baton Rouge. Dr. Moran earned his professional Pharmacy degree, MBA and Pharmaceutical Sciences postgraduate degrees from the University of Louisiana at Monroe.

Dr. Moran has expanded his pharmaceutical formulation experience by completing basic and advanced training at Professional Compounding Centers of America (PCCA) Compounding in Houston, TX; as a trained American Colleges of the Apothecaries Compounding Specialist in Memphis, TN and has completed numerous specialty courses with the National Community Pharmacists Association.

Dr. Moran has completed various extensive training in New York and California through BevNet Live Entrepreneur School annually since 2009, inclusive of branding, packaging, and entrepreneur coursework to enhance his knowledge of the beverage industry. Additionally, he completed advanced packaging solutions, particularly with aluminum cans, at Ball Corporation headquarters in Colorado.

*Public Service:*

Dr. Moran was an active member of the White House Business Forward being chosen to be video recorded for promotional commercial campaign on free-trade in 2016. He was appointed Chair of the Mississippi District Export Council (DEC) which is a position appointed by the United States Department of Commerce (USDC) and United States Export Assistance Council (USEAC). As a member of the MS DEC, Dr. Moran in conjunction with the State's Governor, honored and awarded several Mississippi business leaders annually at special events. Dr. Moran also is a member of the Louisiana State University's College of Science's Executive Committee to help enhance the University's science programs, recruitment and interests.

**Jacob Dillon Houston, President and Chief Operating Officer**

As President and COO, J.D. Houston has responsibility for revenue management and optimization, operational cost containment and capital raises to fund business growth.

Mr. Houston started his career with IBM Global Financing; first as a portfolio manager of end-of-lease technology assets, then as a Global Trader in Asset Services. In just his third year with IBM, he received an "outperform" review; a designation reserved for the elite Top 1% performers company-wide.

Later in his career, he coupled his corporate success and finance experience to help entrepreneurs increase revenue and accelerate growth. Mr. Houston has held various senior management and Sales leadership roles within target companies.

Noteworthy is Mr. Houston's past involvement with I.D. Systems, Inc. which generated significant revenue growth during his tenure as the Director of Sales, North America. Between the years of 2000-2006, the company grew revenue 1,354%; culminating in March 2006 with the Company's secondary public offering of \$60 million in capital and a top ranking on Deloitte's prestigious "Fast 500" list in 2005 and 2006, respectively.

Mr. Houston, a scholar athlete, graduated with honors from South Carolina State University with a Bachelor of Science degree in Business and holds an MBA from the School of Business & Industry at Florida A&M University.

Past and present honors and certifications include Series 7 Securities license, FINRA Registered Rep., and coveted participation in the opening ceremonies of the NASDAQ Stock Exchange.

Mr. Houston currently holds or has held a seat on The Board of Directors/Trustees for The HP Educational Trust and The IBM Black Executive Task Force.

**Dr. Derrick Brooks, Director**

Derrick D. Brooks, Sr., M.D., age 42, is a medical physician whose primary role is to serve as a licensed healthcare profession and medical liaison to assist the company in reviewing opportunities in developing new products that assist in mood enhancement, improving functionality and to serve as an additional medical expert as it relates to the Company’s IP protected relaxation formula used in Lean Slow Motion Potion™ and other relaxation products.

**Professional Experience**

Staff Emergency Room (Physician Level II)  
Our Lady of the Lake Regional Medical Center  
July 2003 - April 2011

Staff Emergency Room Physician (Level II)  
Ochsner Baton Rouge

**Medical Education**

Louisiana State University School of Medicine  
Doctor of Medicine 1999  
New Orleans, Louisiana

**Board Certifications**

American Board of Internal Medicine | Certified 2003  
American Board of Pediatrics | Certified 2003